← Trials/Trial dossier/NCT07121153
A Research Study on How NNC0487-0111, a New Medicine, Works in Chinese Participants When Injected Under the Skin.
Investigation of Safety, Tolerability and Pharmacokinetic Properties of Single Doses of Subcutaneous NNC0487-0111 in Chinese Participants With Overweight or Obesity.
Lead sponsor
Asset
Amycretin / zenagamtide
Oral · GLP-1 / amylin
Listed sites
1
Recruiting sites
—
Enrollment
36
actual
Study population
Obesity / overweight
Key I/E criteria
•BMI 24-34.9•Male
Primary endpoint
•Treatment-emergent AEs (any)
Footprint
Where this trial recruits
Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.
Identifiers
Registered as
Timeline
Milestones
Assets
Investigational agents
Study populations
Who this study enrolls
Eligibility
Who can enroll
Inclusion criteria
1. Informed consent obtained before any study-related activities. Study-related activities are any procedures that are carried out as part of the study, including activities to determine suitability for the study.
2. Male Chinese participants, age 18-55 years (both inclusive) at the time of signing the informed consent.
3. Body mass index between 24.0 and 34.9 kg/m2 (both inclusive) at screening. Overweight and obesity should be due to excess adipose tissue, as judged by the investigator, with a body weight (more than or equal to) ≥ 65.0 kg at screening.
4. Considered eligible based on the medical history, physical examination, and the results of vital signs, electrocardiogram and clinical laboratory tests performed during the screening visit, as judged by the investigator.
Exclusion criteria
1. Any condition, unwillingness or inability which in the investigator's opinion might jeopardise participant's safety or compliance with the protocol.
2. HbA1c ≥ 6.5 percent (%) [48 milimol per mole (mmol/mol)] at screening.
3. Any laboratory safety parameters at screening outside the below laboratory ranges:
Endpoints (7)
What's being measured
Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.
Coverage by outcome category
Weight & body composition
1 endpointRelative change in body weight
Time frame:From baseline Day 1 until completion of the end of study visit (Day 23)
Body weight, % change
percent change from baseline, improvement
Glycemic / diabetes
1 endpointChange in fasting plasma glucose
Time frame:From baseline Day 1 until completion of the end of study visit (Day 23)
Fasting glucose, change
change from baseline, improvement
LOINC 1558-6
Safety / tolerability / PK
5 endpointsNumber of treatment emergent adverse events (TEAEs)
Time frame:From NNC0487-0111 administration (Day 1) to completion of the end of study visit (Day 23)
Treatment-emergent AEs (any)
event count, event
AUC0-∞,SD; the area under the NNC0487-0111 plasma concentration-time curve from time 0 to infinity after a single dose
Time frame:From pre-dose on Day 1 until completion of the end of study visit (Day 23)
AUC₀–∞
concentration, descriptive
Cmax,SD; the maximum plasma concentration of NNC0487-0111 after a single dose
Time frame:From pre-dose on Day 1 until completion of the end of study visit (Day 23)
Cmax
concentration, descriptive
tmax,SD; the time of maximum plasma concentration of NNC0487-0111 after a single dose
Time frame:From pre-dose on Day 1 until completion of the end of study visit (Day 23)
Tmax
descriptive
t1/2,SD; the terminal half-life of NNC0487-0111 after a single dose
Time frame:From pre-dose on Day 1 until completion of the end of study visit (Day 23)
Half-life
descriptive
Provenance
Sources
Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.